Shares of Advanced Cell Technology Inc. (OTC: ACTC), a biotechnology company engaged in the development and commercialization of human embryonic, induced pluripotency, and adult stem cell technology in the field of regenerative medicine, are climbing in trading today.
At last check, ACTC shares were trading 4.72% higher at $0.0910 on above average volume of 7.42 million. The stock gained 12.62% in the last three trading sessions.
ACTC shares are gaining today after the company announced treatment of the fourth patient, the first in the second patient cohort, in its Phase 1/2 clinical trial for dry-age related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
Gary Rabin, Chairman and CEO of Advanced Cell Technology, said that ACTC is very pleased to have the second dose cohort in both of its U.S. clinical trials underway.
Recent Comments